CA2016841C - Methode de production de polymeres ayant une activite choisie - Google Patents

Methode de production de polymeres ayant une activite choisie

Info

Publication number
CA2016841C
CA2016841C CA 2016841 CA2016841A CA2016841C CA 2016841 C CA2016841 C CA 2016841C CA 2016841 CA2016841 CA 2016841 CA 2016841 A CA2016841 A CA 2016841A CA 2016841 C CA2016841 C CA 2016841C
Authority
CA
Canada
Prior art keywords
coding
primers
dna
antibody
repertoire
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA 2016841
Other languages
English (en)
Other versions
CA2016841A1 (fr
Inventor
William D. Huse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Clinic and Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic and Research Foundation filed Critical Scripps Clinic and Research Foundation
Publication of CA2016841A1 publication Critical patent/CA2016841A1/fr
Application granted granted Critical
Publication of CA2016841C publication Critical patent/CA2016841C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA 2016841 1989-05-16 1990-05-15 Methode de production de polymeres ayant une activite choisie Expired - Lifetime CA2016841C (fr)

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
US35292789A 1989-05-16 1989-05-16
US35323589A 1989-05-16 1989-05-16
US07/353,235 1989-05-16
US07/352,927 1989-05-16
US35324189A 1989-05-17 1989-05-17
US35288489A 1989-05-17 1989-05-17
US07/352,884 1989-05-17
US07/353,241 1989-05-17
US41073589A 1989-09-20 1989-09-20
US41074989A 1989-09-20 1989-09-20
US41071689A 1989-09-20 1989-09-20
US41088889A 1989-09-20 1989-09-20
US07/410,749 1989-09-20
US07/410,735 1989-09-20
US07/410,716 1989-09-20
US07/410,888 1989-09-20
US41105889A 1989-09-21 1989-09-21
US07/411,058 1989-09-21
US44633389A 1989-12-04 1989-12-04
US07/446,333 1989-12-04
US49710690A 1990-03-20 1990-03-20
US07/497,106 1990-03-20

Publications (2)

Publication Number Publication Date
CA2016841A1 CA2016841A1 (fr) 1990-11-16
CA2016841C true CA2016841C (fr) 1999-09-21

Family

ID=27582782

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2016841 Expired - Lifetime CA2016841C (fr) 1989-05-16 1990-05-15 Methode de production de polymeres ayant une activite choisie

Country Status (6)

Country Link
EP (1) EP0472638B1 (fr)
JP (1) JP3321159B2 (fr)
AU (1) AU651065B2 (fr)
CA (1) CA2016841C (fr)
PT (1) PT94066B (fr)
WO (1) WO1990014424A1 (fr)

Families Citing this family (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993813A (en) * 1988-10-19 1999-11-30 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
US6051225A (en) 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
US6641999B1 (en) 1988-10-19 2003-11-04 The Dow Chemical Company Probing method for identifying antibodies specific for selected antigens
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US6291160B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
CA2016842A1 (fr) * 1989-05-16 1990-11-16 Richard A. Lerner Methode pour puiser dans le repertoire immunologique
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
DK0440147T3 (da) † 1990-02-01 2005-01-17 Dade Behring Marburg Gmbh Fremstilling og anvendelse af genbanker af humant antistof ("humant-antistof-biblioteker")
AU7791991A (en) * 1990-04-24 1991-11-11 Stratagene Methods for phenotype creation from multiple gene populations
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
GB9206318D0 (en) * 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
JPH06508511A (ja) * 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
IL99552A0 (en) * 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
NZ241119A (en) * 1990-12-20 1993-06-25 Ixsys Inc Manipulating nucleic acid to optimize the binding characteristics of the encoded binding protein
ATE414768T1 (de) * 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
US5955341A (en) * 1991-04-10 1999-09-21 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
US5962255A (en) * 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5858657A (en) * 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
DK1696031T3 (da) * 1991-12-02 2010-08-02 Medimmune Ltd Fremstilling af anti-autoantigener fra antistofsegmentrepertoirer og præsentere på fag
DK0616640T3 (da) * 1991-12-02 2004-12-20 Medical Res Council Fremstilling af anti-selv antistoffer fra repertoirer af antistofsegmenter og fremvist på fag
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0663953B1 (fr) * 1992-09-04 2001-12-05 The Scripps Research Institute Phagemides coexprimant un recepteur de surface et une proteine heterologue de surface
AU6235294A (en) 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
DE69531148T2 (de) * 1994-01-31 2004-04-29 Trustees Of Boston University, Boston Bibliotheken aus polyklonalen antikörpern
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6046037A (en) * 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US6054567A (en) 1997-04-11 2000-04-25 The United States Of America As Represented By The Department Of Health And Human Services Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
EP1690868A1 (fr) 1997-10-31 2006-08-16 Maxygen, Inc. Modification du tropisme viral et de la diversité d'espèces hôte par recombinaison du génome viral
EP1036198B1 (fr) 1997-12-08 2012-09-26 California Institute Of Technology Procédé de préparation des séquences de polynucléotides et de polypeptides
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
AU3719500A (en) 1999-03-05 2000-09-21 Maxygen, Inc. Recombination of insertion modified nucleic acids
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
JP4776852B2 (ja) 2000-01-28 2011-09-21 アメリカ合衆国 癌抗原ｎｙｅｓｏ−１由来の新規ｍｈｃクラスｉｉ拘束ｔ細胞エピトープ
DE60100814T2 (de) * 2000-06-08 2004-07-01 Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh Immunstimulierende oligodeoxynukleotide
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
JP4368196B2 (ja) 2000-11-17 2009-11-18 ユニバーシティー オブ ロチェスター 真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法
EP1355666B1 (fr) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Utilisation de "repulsive guidance molecule" (RGM) et de ses modulateurs
ES2436206T3 (es) 2001-11-14 2013-12-27 Janssen Biotech, Inc. Anticuerpos anti il-6, composiciones, métodos y usos
EP3031910B1 (fr) 2002-02-21 2017-08-16 Institute Of Virology Anticorps monoclonaux spécifiques au mn/ca ix générés à partir de souris déficientes en mn/ca ix et procédés d'utilisation
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
NZ596992A (en) 2005-06-30 2013-07-26 Abbott Lab Il-12/p40 binding proteins
PT2452694T (pt) 2005-06-30 2019-02-21 Janssen Biotech Inc Anticorpos anti-il-23, composições, métodos e utilizações
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500357A3 (fr) 2005-08-19 2012-10-24 Abbott Laboratories Immunoglobuline à double domaine variable et ses utilisations
EP2500352A1 (fr) 2005-08-19 2012-09-19 Abbott Laboratories Immunoglobuline à double domaine variable et ses utilisations
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
EA035459B1 (ru) 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
KR101544108B1 (ko) 2006-09-08 2015-08-13 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8663980B2 (en) 2007-10-26 2014-03-04 Janssen Biotech, Inc. Vectors, host cells, and methods of production and uses
JP5580205B2 (ja) 2007-11-19 2014-08-27 セレラ コーポレーション 肺癌マーカーとその使用
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
KR101649168B1 (ko) 2008-05-09 2016-08-18 애브비 인코포레이티드 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도
AR072000A1 (es) 2008-06-03 2010-07-28 Abbott Lab Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
RU2010151562A (ru) 2008-06-20 2012-07-27 ВАЙЕТ ЭлЭлСи (US) Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов
BRPI0915448A2 (pt) 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
BRPI0915825A2 (pt) 2008-07-08 2015-11-03 Abbott Lab proteínas de ligação à prostaglandina e2 usos das mesmas
AR073060A1 (es) 2008-08-14 2010-10-13 Arana Therapeutic Ltd Anticuerpos anti-il-12/il-23
SG172855A1 (en) 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
SG173705A1 (en) 2009-03-05 2011-09-29 Abbott Lab Il-17 binding proteins
AU2010249470B2 (en) 2009-05-20 2015-06-25 Novimmune S.A. Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
NZ596603A (en) 2009-05-29 2013-07-26 Morphosys Ag A collection of antibodies or fragments having properties relevant to developability
MX336152B (es) 2009-08-29 2016-01-08 Abbvie Inc Proteinas terapeutico de union a dll4.
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8420083B2 (en) 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
MX2012006560A (es) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
WO2011100403A1 (fr) 2010-02-10 2011-08-18 Immunogen, Inc Anticorps anti-cd20 et utilisations de ceux-ci
TWI672318B (zh) 2010-02-24 2019-09-21 美商免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
EP3072904A1 (fr) 2010-03-02 2016-09-28 Abbvie Inc. Protéines de liaison dll4 thérapeutiques
CA2795043C (fr) 2010-03-30 2019-04-23 Janssen Biotech, Inc. Anticorps humanises de il-25
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
MY161302A (en) 2010-05-14 2017-04-14 Abbvie Inc IL-1 binding proteins
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3252072A3 (fr) 2010-08-03 2018-03-14 AbbVie Inc. Immunoglobuline à double domaine variable et ses utilisations
EP3533803B1 (fr) 2010-08-14 2021-10-27 AbbVie Inc. Anticorps anti-bêta-amyloïde
JP6121903B2 (ja) 2010-08-19 2017-04-26 ゾエティス・ベルジャム・エス・アー 抗ｎｇｆ抗体およびその使用
SG187938A1 (en) 2010-08-26 2013-04-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
SG189950A1 (en) 2010-11-19 2013-06-28 Morphosys Ag A collection and methods for its use
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
AU2011361720B2 (en) 2010-12-21 2017-04-27 Abbvie Inc. IL-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
MX344595B (es) 2010-12-31 2016-12-20 Bioatla Llc Humanizacion rapida de anticuerpos.
AU2012283039A1 (en) 2011-07-13 2014-01-30 Abbvie Inc. Methods and compositions for treating asthma using anti-IL-13 antibodies
UY34411A (es) 2011-10-24 2013-05-31 Abbvie Inc Inmunoenlazantes dirigidos contra esclerostina
AU2012340766B2 (en) 2011-11-23 2018-05-10 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
CN104159920A (zh) 2011-12-30 2014-11-19 艾伯维公司 针对il-13和/或il-17的双重可变结构域免疫球蛋白
PE20190907A1 (es) 2012-01-27 2019-06-26 AbbVie Deutschland GmbH and Co KG Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
CN104379602B (zh) 2012-03-08 2017-05-03 哈洛齐梅公司 具有条件活性的抗表皮生长因子受体抗体及其使用方法
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
WO2014011955A2 (fr) 2012-07-12 2014-01-16 Abbvie, Inc. Protéines de liaison à il-1
PL2890717T3 (pl) 2012-08-31 2020-08-10 Immunogen, Inc. Testy i zestawy diagnostyczne do wykrywania receptora folianu
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
BR112015023239A8 (pt) 2013-03-14 2018-04-17 Abbott Lab ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
MX376492B (es) 2013-03-14 2025-03-07 Abbott Lab Anticuerpos monoclonares que se unen al dominio de unión a lípidos de la proteína de la cápside del virus de la hepatitis c (vhc)
MX2015012824A (es) 2013-03-14 2016-06-24 Abbott Lab Antigenos recombinantes ns3 del vhc y mutantes de los mismos para la deteccion mejorada de anticuerpos.
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
CN105814079B (zh) 2013-08-30 2021-02-09 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
SG11201601770YA (en) 2013-09-12 2016-04-28 Halozyme Inc Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
RS63295B1 (sr) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Anti-vista antitela i fragmenti
MA39821B1 (fr) 2014-04-08 2020-09-30 Boston Pharmaceuticals Inc Molécules de liaison spécifiques de l'il-21 et leurs utilisations
ES2819863T3 (es) 2014-04-11 2021-04-19 Medimmune Llc Anticuerpos contra HER2 biespecíficos
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
MX385320B (es) 2014-11-10 2025-03-18 Medimmune Ltd Moléculas de unión específicas para grupo de diferenciación 73 (cd73) y usos de las mismas.
WO2016075176A1 (fr) 2014-11-11 2016-05-19 Medimmune Limited Combinaisons thérapeutiques contenant des anticorps anti-cd73 et des inhibiteurs du récepteur a2a et utilisations desdites combinaisons
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
CA2973978A1 (fr) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Inc. Traitement du cancer avec des anticorps monoclonaux anti-lap
RU2715597C2 (ru) 2015-05-29 2020-03-02 Эббви Инк. Антитела к cd40 и способы их применения
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
EP3842459A1 (fr) 2015-06-29 2021-06-30 ImmunoGen, Inc. Anticorps anti-cd 123 et conjugués et dérivés correspondants
SG10202103712VA (en) 2015-11-10 2021-05-28 Medimmune Llc Binding molecules specific for asct2 and uses thereof
CN109069626A (zh) 2016-02-12 2018-12-21 詹森药业有限公司 抗-vista(b7h5)抗体
HRP20241557T1 (hr) 2016-03-10 2025-05-23 Acceleron Pharma Inc. Proteini koji vezuju receptor aktivina tipa 2 i njihova uporaba
WO2017161206A1 (fr) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugués contenant des anticorps à activité conditionnelle ou des fragments de liaison à un antigène associés, et procédés d'utilisation
MA44510A (fr) 2016-03-29 2021-03-31 Janssen Biotech Inc Methode de traitement du psoriasis avec dosage intervalle augmenté d'anticorps anti-il12 et/ou -23
WO2017175058A1 (fr) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anticorps anti-vista et fragments de ceux-ci, leurs utilisations et leurs procédés d'identification
CA3018272A1 (fr) 2016-04-22 2017-10-26 Acceleron Pharma Inc. Proteines de liaison a alk7 et leurs utilisations
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
SG10202001787QA (en) 2016-06-02 2020-04-29 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
CN109641962A (zh) 2016-06-08 2019-04-16 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
RS61828B1 (sr) 2016-06-08 2021-06-30 Abbvie Inc Anti-b7-h3 antitela i antitelske konjugacije lekova
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
DK3519049T3 (da) 2016-09-30 2026-01-12 Janssen Biotech Inc Sikker og effektiv fremgangsmåde til behandling af psoriasis med specifikt anti-il23-antistof
KR20240065333A (ko) 2016-11-16 2024-05-14 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 방법
WO2018098370A1 (fr) 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. Protéines de liaison à 4-1bb et leurs utilisations
JP7227146B2 (ja) 2016-11-23 2023-02-21 バイオベラティブ セラピューティクス インコーポレイテッド 凝固第ｉｘ因子および凝固第ｘ因子に結合する二重特異性抗体
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN110709419B (zh) 2017-01-06 2023-11-28 博奥信生物技术（南京）有限公司 Erbb2抗体及其用途
EP3573658A4 (fr) 2017-01-30 2021-07-21 Janssen Biotech, Inc. Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
KR20190115042A (ko) 2017-02-07 2019-10-10 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
JP6889328B2 (ja) 2017-07-31 2021-06-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 三次元構造に基づくヒト化方法
IL272840B2 (en) 2017-09-05 2025-01-01 Immunogen Inc Methods for detecting folate receptor 1 in a patient sample
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3694552A1 (fr) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anticorps anti-lap et leurs utilisations
WO2019090329A1 (fr) 2017-11-06 2019-05-09 Janssen Biotech, Inc. Méthode sûre et efficace de traitement de l'arthrite psoriasique par un anticorps spécifique anti-il23
WO2019150309A1 (fr) 2018-02-02 2019-08-08 Hammack Scott Modulateurs de gpr68 et leurs utilisations pour le traitement et la prévention de maladies
CA3091184A1 (fr) 2018-02-14 2019-08-22 Viela Bio, Inc. Anticorps diriges contre le ligand du recepteur 3 de la tyrosine kinase 3 du sarcome de mcdonough felin (fms) (flt3l) et leurs utilisations pour le traitement de maladies auto-imm unes et inflammatoires
IL276896B2 (en) 2018-03-05 2024-06-01 Janssen Biotech Inc Methods of treating crohn's disease with anti-il23 specific antibody
CA3093772C (fr) 2018-03-12 2024-04-16 Zoetis Services Llc Anticorps anti-ngf et procedes associes
US12543710B2 (en) 2018-06-08 2026-02-10 Crystal Bioscience Inc. Transgenic animal for producing diversified antibodies that have the same light chain II
JP7515410B2 (ja) 2018-06-13 2024-07-12 クリスタル バイオサイエンス インコーポレイテッド 複数のジスルフィド架橋によって安定化され、遺伝子変換によって多様化された長いｃｄｒ－ｈ３ｓで抗体を作製するトランスジェニックニワトリ
KR20210021024A (ko) 2018-06-13 2021-02-24 크리스탈 바이오사이언스 주식회사 유전자 변환에 의한 자율 중쇄 가변 도메인의 수정에 의한 항체 생산
WO2020014306A1 (fr) 2018-07-10 2020-01-16 Immunogen, Inc. Anticorps anti-met, immunoconjugués et utilisations de ceux-ci
WO2020016838A2 (fr) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Prédicteurs de réponse prolongée après le traitement avec un anticorps spécifique anti-il23
MD3883606T3 (ro) 2018-09-24 2024-03-31 Janssen Biotech Inc Metodă sigură și eficientă de tratament al colitei ulcerative cu anticorpi anti-IL12/IL23
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
BR112021009287A2 (pt) 2018-11-20 2021-10-26 Janssen Biotech, Inc. Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
JP7463366B2 (ja) 2018-11-20 2024-04-08 タケダ ワクチン，インコーポレイテッド 新規の抗ジカウイルス抗体及びその使用
EP3897722A4 (fr) 2018-12-18 2022-09-14 Janssen Biotech, Inc. Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
US12467062B2 (en) 2018-12-21 2025-11-11 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
KR20210116540A (ko) 2019-01-15 2021-09-27 얀센 바이오테크 인코포레이티드 소아 특발성 관절염의 치료를 위한 항-tnf 항체 조성물 및 방법
EP3914618A1 (fr) 2019-01-23 2021-12-01 Janssen Biotech, Inc. Compositions d'anticorps anti-tnf destinées à être utilisées dans des méthodes de traitement d'arthrite psoriasique
CA3133383A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procedes de production de compositions d'anticorps anti-tnf
CA3133395A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methodes de fabrication permettant de produire des compositions d'anticorps anti-il12/il23
WO2020183271A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procédés de production de compositions d'anticorps anti-tnf
WO2020183269A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
MA55383A (fr) 2019-03-18 2022-01-26 Janssen Biotech Inc Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
MA56015A (fr) 2019-06-03 2022-04-06 Janssen Biotech Inc Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique
MX2021014882A (es) 2019-06-03 2022-03-25 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa.
AU2020288749A1 (en) 2019-06-04 2022-02-03 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
WO2021028752A1 (fr) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anticorps anti-tfn pour le traitement du diabète de type i
WO2021159024A1 (fr) 2020-02-05 2021-08-12 Larimar Therapeutics, Inc. Protéines de liaison au peptide tat et leurs utilisations
EP4132971A1 (fr) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Anticorps anti-lap à maturation d'affinité et leurs utilisations
CA3181949A1 (fr) 2020-05-05 2021-11-11 Janssen Biotech, Inc. Procedes de traitement de la maladie de crohn au moyen d'un anticorps specifique anti-il23
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
US20220025035A1 (en) 2020-07-13 2022-01-27 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
US20220073603A1 (en) 2020-07-30 2022-03-10 Janssen Biotech, Inc. Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
US11795225B2 (en) 2020-09-11 2023-10-24 Medimmune Limited Therapeutic binding molecules
EP4211663B1 (fr) 2020-09-12 2026-02-18 MedImmune Limited Méthode de notation associée à une thérapie par conjugué anticorps-anti-b7h4-médicament
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022190034A1 (fr) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Méthode de traitement de patients souffrant de polyarthrite psoriasique ayant une réponse inadéquate à une thérapie par tnf avec un anticorps spécifique anti-il23
WO2022190033A1 (fr) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23
CA3208011A1 (fr) 2021-03-17 2022-09-22 Sarah Harris Methodes de traitement de la dermatite atopique avec des anticorps anti il-13
CR20230488A (es) 2021-03-18 2023-12-12 Medimmune Ltd Moléculas de unión terapéuticas
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
CN117916260A (zh) 2021-07-09 2024-04-19 詹森生物科技公司 用于制备抗il12/il23抗体组合物的制造方法
WO2023281462A1 (fr) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Procédés de fabrication pour produire des compositions d'anticorps anti-tnf
CN117957251A (zh) 2021-07-09 2024-04-30 詹森生物科技公司 用于制备抗tnf抗体组合物的制造方法
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
KR20240099352A (ko) 2021-10-29 2024-06-28 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
WO2023084488A1 (fr) 2021-11-15 2023-05-19 Janssen Biotech, Inc. Méthodes de traitement de la maladie de crohn au moyen d'un anticorps spécifique anti-il23
KR20240103043A (ko) 2021-11-23 2024-07-03 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
CN119698430A (zh) 2022-03-30 2025-03-25 詹森生物科技公司 用il-23特异性抗体治疗轻度至中度银屑病的方法
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
IL321059A (en) 2022-11-22 2025-07-01 Janssen Biotech Inc Method for treating ulcerative colitis with a specific anti-IL23 antibody
CN120659814A (zh) 2023-02-13 2025-09-16 浙江大学绍兴研究院 双特异性抗体及其应用
AU2024318876A1 (en) 2023-07-31 2026-03-19 Astrazeneca Ab Cd123 antibody-drug conjugates and methods of using the same
WO2025184208A1 (fr) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anticorps anti-ceacam5 et leurs utilisations
CA3249015A1 (en) 2024-03-20 2025-10-31 Janssen Biotech, Inc. Methods of treating crohn’s disease with anti-il23 specific antibody
WO2025262604A1 (fr) 2024-06-17 2025-12-26 Janssen Biotech, Inc. Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23
WO2026003761A1 (fr) 2024-06-27 2026-01-02 Janssen Biotech, Inc. Méthodes de traitement de la rectocolite hémorragique avec un anticorps spécifique anti-il23

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656134A (en) * 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
DE3382317D1 (de) * 1982-03-15 1991-07-25 Schering Corp Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer.
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
WO1988006630A1 (fr) * 1987-03-02 1988-09-07 Genex Corporation Procede de preparation de molecules de liaison
AU612370B2 (en) * 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
AU2318288A (en) * 1987-08-07 1989-03-09 Genelabs Incorporated Coincidence cloning method and library
FI903489A0 (fi) * 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.

Also Published As

Publication number Publication date
JPH05501348A (ja) 1993-03-18
EP0472638B1 (fr) 2000-10-11
JP3321159B2 (ja) 2002-09-03
EP0472638A4 (en) 1992-08-19
AU651065B2 (en) 1994-07-14
CA2016841A1 (fr) 1990-11-16
EP0472638A1 (fr) 1992-03-04
PT94066B (pt) 1997-01-31
AU5673390A (en) 1990-12-18
PT94066A (pt) 1991-01-08
WO1990014424A1 (fr) 1990-11-29

Similar Documents

Publication Publication Date Title
CA2016841C (fr) Methode de production de polymeres ayant une activite choisie
US6291159B1 (en) Method for producing polymers having a preselected activity
EP1026239B1 (fr) Nouveau procédé d'exploitation du répertoire immunologique
US6291158B1 (en) Method for tapping the immunological repertoire
US6291160B1 (en) Method for producing polymers having a preselected activity
US6291161B1 (en) Method for tapping the immunological repertiore
US6680192B1 (en) Method for producing polymers having a preselected activity
US6969586B1 (en) Method for tapping the immunological repertoire
EP0528881A1 (fr) Procedes de creation de phenotype a partir de populations de genes multiples
US7118866B2 (en) Heterodimeric receptor libraries using phagemids
CN107922950B (zh) T细胞受体文库
IE84214B1 (en) Heterodimeric receptor libraries using phagemids

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry